Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy - Scorecard - MDSpire

Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy

  • By

  • Anita Muglia

  • Daniele Petrone

  • Ilaria Schiavoni

  • Letizia Santinelli

  • Pasqualina Leone

  • Antonino Bella

  • Gabriella d’Ettorre

  • Francesco Alessandri

  • Anna Teresa Palamara

  • Claudio Maria Mastroianni

  • Paola Stefanelli

  • Giorgio Fedele

  • May 25, 2026

  • 0 min

Share

Clinical Scorecard: Cytokine Profile Analysis Identifies CXCL10 (IP-10) as a Significant Indicator of Severe COVID-19 Outcomes in Hospitalized Patients During Italy's Initial Pandemic Wave

At a Glance

CategoryDetail
ConditionCOVID-19
Key MechanismsDysregulated inflammatory responses and cytokine storm
Target PopulationHospitalized COVID-19 patients
Care SettingHospital

Key Highlights

  • Each 1,000 pg/mL increase in CXCL10 correlates with higher odds of death and ICU admission.
  • ICU admission occurred in 6.8% of patients; mortality was 11.7%.
  • IL-6 and other cytokines were not significant predictors in multivariable models.

Guideline-Based Recommendations

Diagnosis

  • Utilize cytokine and chemokine profiles for early risk assessment in COVID-19 patients.

Management

    Monitoring & Follow-up

    • Monitor CXCL10 levels as part of the inflammatory response assessment.

    Risks

    • Increased CXCL10 levels are associated with higher mortality and ICU admission.

    Patient & Prescribing Data

    103 RT-PCR-confirmed COVID-19 patients

    CXCL10 may represent a potential therapeutic target.

    Clinical Best Practices

      Related Resources & Content

      Original Source(s)

      Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy

      • by Anita Muglia, Daniele Petrone, Ilaria Schiavoni, Letizia Santinelli, Pasqualina Leone, Antonino Bella, Gabriella d’Ettorre, Francesco Alessandri, Anna Teresa Palamara, Claudio Maria Mastroianni, Paola Stefanelli, Giorgio Fedele

      • May 25, 2026

      Related Content

      Recent COVID-19 Shot Linked to Less Spread

      Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.

      Assessing PEPFAR’s Economic and Educational Spillover Effects: An Update

      Long COVID as a network disorder: a mechanism-anchored framework for biological stratification and therapeutic targeting